The UAE is the first country in the Middle East region to approve QSYMIA and have it available in market. This marks an important milestone for patients challenged by obesity and the physicians who treat them. VIVUS, in collaboration with PharmaAccess, its marketing partner in the Middle East North African (MENA) region, intends to provide healthcare providers with more treatment options to combat this epidemic in line with the UAE vision to address obesity. Alphamed Drug Store is the exclusive distributor of QSYMIA in the UAE. "VIVUS remains steadfast in its mission to tackle the obesity crisis head-on," said John Amos, Chief Executive Officer at VIVUS LLC."With the availability of QSYMIA in the UAE, we're not only expanding treatment access but also reaffirming our commitment to advancing patient care on a global scale. We are enthusiastic about our continued progress in combatting this urgent public health concern, making a meaningful impact in communities worldwide."